Nasopharyngeal eosinophil cationic protein in bronchiolitis: relation to viral findings and subsequent wheezing.
A prospective 4-month follow-up of children hospitalized with bronchiolitis revealed that high concentrations of eosinophil cationic protein (ECP) in nasopharyngeal aspirates (NPA) are predictive of wheezing after bronchiolitis. In the 29 patients who received no anti-inflammatory therapy the median concentration of NPA ECP was 882 ng/g in those with physician-diagnosed wheezing (P = 0.02). The NPA ECP concentration of the whole study group of 88 children with and without subsequent hospital admissions for wheezing were 531 and 299 ng/g, respectively (P = 0.02). At entry the children with negative viral findings had significantly higher concentrations of respiratory tract ECP than those with positive viral findings (515 vs. 240 ng/g; P = 0.01). The concentration of ECP in respiratory secretions decreased significantly after bronchiolitis (P = 0.01) provided that no new viral or mycoplasmal infection occurred. NPA ECP values decreased in relation to time regardless of whether anti-inflammatory therapy was used or not. Children with high concentrations of respiratory tract ECP seemed to benefit from anti-inflammatory therapy with nebulized cromolyn sodium or budesonide; both drugs significantly decreased the number of subsequent physician-diagnosed bronchial obstruction (P = 0.0006), and they tended to decrease the number of hospital admissions for wheezing (P = 0.08). Our results suggest that high concentrations of ECP in respiratory tract secretions in children with bronchiolitis reflect the presence of eosinophilic inflammation also seen in asthma.
Reijonen
T M
TM
Department of Pediatrics, Kuopio University Hospital, Finland.
Korppi
M
M
Kleemola
M
M
Savolainen
K
K
Kuikka
L
L
Mononen
I
I
Remes
K
K
D000208:Acute Disease; D001798:Blood Proteins / Q000032:analysis*; D001988:Bronchiolitis / Q000378:metabolism* / Q000821:virology; D047091:Eosinophil Granule Proteins; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D017817:Nasal Lavage Fluid / Q000737:chemistry* / Q000821:virology; D011446:Prospective Studies; D012135:Respiratory Sounds / Q000503:physiopathology*; D012260:Ribonucleases; D013997:Time Factors
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D012260:Ribonucleases